LEXICON PHARMACEUTICALS, INC. Selling, General and Administrative Expense
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Selling, General and Administrative Expense of $9.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $9.75M, a 4.28% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $9.23M, a 20.45% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $8.76M, a 72.85% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $7.60M, a 80.80% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2025 was $37.32M, a 73.92% decline from fiscal 2024.
- LEXICON PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2024 was $143.10M, a 25.55% increase from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2023 was $113.98M, a 137.05% increase from fiscal 2022.
- LEXICON PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2022 was $48.08M, a 48.67% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.75M 10-Q · filed 2026-08-06 | $18.98M 10-Q · filed 2026-08-06 | $27.74M derived: sum of 3 quarters · filed 2026-08-06 | $35.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $9.23M 10-Q · filed 2026-05-07 | $17.99M derived: sum of 2 quarters · filed 2026-05-07 | $25.59M derived: sum of 3 quarters · filed 2026-05-07 | $34.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $8.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $16.36M derived: sum of 2 quarters · filed 2026-03-05 | $25.71M derived: sum of 3 quarters · filed 2026-08-06 | $37.32M 10-K · filed 2026-03-05 |
| 2025-09-30 | $7.60M 10-Q · filed 2025-11-06 | $16.95M derived: sum of 2 quarters · filed 2026-08-06 | $28.56M 10-Q · filed 2025-11-06 | $60.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $9.35M 10-Q · filed 2026-08-06 | $20.96M 10-Q · filed 2026-08-06 | $53.22M derived: sum of 3 quarters · filed 2026-08-06 | $92.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $11.61M 10-Q · filed 2026-05-07 | $43.87M derived: sum of 2 quarters · filed 2026-05-07 | $83.46M derived: sum of 3 quarters · filed 2026-05-07 | $122.65M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $32.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $71.85M derived: sum of 2 quarters · filed 2026-03-05 | $111.04M derived: sum of 3 quarters · filed 2026-03-05 | $143.10M 10-K · filed 2026-03-05 |
| 2024-09-30 | $39.59M 10-Q · filed 2025-11-06 | $78.78M derived: sum of 2 quarters · filed 2025-11-06 | $110.84M 10-Q · filed 2025-11-06 | $143.45M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $39.19M 10-Q · filed 2025-08-06 | $71.25M 10-Q · filed 2025-08-06 | $103.86M derived: sum of 3 quarters · filed 2026-03-05 | $136.09M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $32.06M 10-Q · filed 2025-05-14 | $64.67M derived: sum of 2 quarters · filed 2026-03-05 | $96.89M derived: sum of 3 quarters · filed 2026-03-05 | $126.90M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $32.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $64.83M derived: sum of 2 quarters · filed 2026-03-05 | $94.84M derived: sum of 3 quarters · filed 2026-03-05 | $113.98M 10-K · filed 2026-03-05 |
| 2023-09-30 | $32.23M 10-Q · filed 2024-11-13 | $62.24M derived: sum of 2 quarters · filed 2024-11-13 | $81.38M 10-Q · filed 2024-11-13 | $97.70M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-06-30 | $30.01M 10-Q · filed 2024-08-02 | $49.15M 10-Q · filed 2024-08-02 | $65.48M derived: sum of 3 quarters · filed 2025-03-07 | $78.05M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-03-31 | $19.14M 10-Q · filed 2024-05-02 | $35.47M derived: sum of 2 quarters · filed 2025-03-07 | $48.05M derived: sum of 3 quarters · filed 2025-03-07 | |
| 2022-12-31 | $16.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $28.91M derived: sum of 2 quarters · filed 2025-03-07 | $48.08M 10-K · filed 2025-03-07 | |
| 2022-09-30 | $12.58M 10-Q · filed 2023-11-08 | $31.75M 10-Q · filed 2023-11-08 | ||
| 2021-12-31 | $32.34M 10-K · filed 2024-03-25 | |||
| 2018-03-31 | $14.86M 10-Q · filed 2018-05-03 | |||
| 2017-09-30 | $16.72M 10-Q · filed 2017-11-08 | $35.20M derived: sum of 2 quarters · filed 2017-11-08 | $50.07M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $18.48M 10-Q · filed 2017-08-01 | $33.35M 10-Q · filed 2017-08-01 | ||
| 2017-03-31 | $14.87M 10-Q · filed 2018-05-03 | |||
| 2016-09-30 | $12.26M 10-Q · filed 2017-11-08 | $20.68M derived: sum of 2 quarters · filed 2017-11-08 | $29.08M 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $8.42M 10-Q · filed 2017-08-01 | $16.81M 10-Q · filed 2017-08-01 | ||
| 2016-03-31 | $8.40M 10-Q · filed 2017-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |